Rakovina Therapeutics

Our Drug Development Pipeline

Product Development Pipeline


Deep Docking™: AI Driven Discovery of Best-in-Class Cancer Therapies

Beyond the success of PARP inhibitors, the field of DNA-damage response inhibition has unveiled a wealth of promising targets for cancer treatment.

The emergence of new targets provides a rich landscape of potential strategies poised to revolutionize the treatment of cancer.

kt-3000 series

Rakovina Therapeutics’ kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly(ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule.

This novel approach has the potential to overcome treatment resistance and provide meaningful clinical benefit to cancer patients.